Recombinant Human LILRA2 protein (rFc Tag)

Species

Human

Purity

>90 %, SDS-PAGE

Tag

rFc Tag

Activity

not tested

Cat no : Eg1746

---

Validation Data Gallery

• 

  Purity of Recombinant Human LILRA2 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.

---

Product Information

• Purity: >90 %, SDS-PAGE
• Endotoxin: <0.1 EU/μg protein, LAL method
• Activity:

  Not tested

• Expression: HEK293-derived Human LILRA2 protein Gly24-Asn449 (Accession# Q8N149-1) with a rabbit IgG Fc tag at the C-terminus.
• GeneID: 11027
• Accession: Q8N149-1
• PredictedSize: 73.2 kDa
• SDS-PAGE: 80-110 kDa, reducing (R) conditions
• Formulation: Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
• Reconstitution: Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
• Storage Conditions:
  It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
• Shipping: The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

LILRA2, also known as CD85H and ILT1, is a member of the subfamily A class of LIR receptors (LILRAs). LILRA2 is an activating receptor highly expressed in inflammatory tissues, and is involved in granulocyte and macrophage activation. Cross-linking of LILRA2 on the surface of leukocytes recruits protein tyrosine kinase signaling molecules that lead to cellular activation. It can inhibit dendritic cell differentiation and antigen presentation and suppresses innate immune responses. It plays a role in the innate immune responses against microbial infection and modulates LPS-mediated cytokine production and inhibits phagocytosis by monocytes.

References:

1. Mamegano K, et al. (2008). Genes Immun. 9(3):214-223.
2. Nakajima H, et al. (1999). J Immunol. 162(1):5-8.
3. Lu HK, et al. (2012). PLoS One.7(8).